Literature DB >> 28711194

Factors associated with epinephrine administration for anaphylaxis in children before arrival to the emergency department.

Melissa Robinson1, Matthew Greenhawt2, David R Stukus3.   

Abstract

BACKGROUND: Epinephrine is the first-line treatment for anaphylaxis but may be underused by patients and medical personnel.
OBJECTIVE: To evaluate factors associated with anaphylaxis management before arrival at the emergency department (ED) or urgent care center (UCC).
METHODS: We performed a retrospective review of electronic medical records for all patients aged 0 to 25 years presenting with anaphylaxis to the ED or UCC at a pediatric academic referral center during 2009 to 2013.
RESULTS: A total of 408 patients (mean age, 7.25 years; 62% male) were included for analysis. Only 148 patients (36.3%) received epinephrine before arrival at the ED or UCC. Reactions occurring at home (n = 36/114) were less likely to be treated with epinephrine compared with reactions occurring at school (n = 30/49) (odds ratio [OR], 0.29; 95% confidence interval [CI], 0.15-0.59). The odds of receiving epinephrine before arrival at the ED or UCC were significantly lower with a 2-organ system (OR, 0.50; 95% CI, 0.30-0.85) or 3-organ system (OR, 0.41; 95% CI, 0.21-0.81) presentation compared with 1-organ system involvement. Foods (342 [83.8%]) were the most commonly reported provoking trigger. Patients who did not receive epinephrine before arrival at the ED or UCC were significantly less likely to be discharged to home (OR, 0.56; 95% CI, 0.37-0.86; P = .01).
CONCLUSION: This study identifies factors associated with prehospital management of anaphylaxis for children, which highlight that epinephrine administration may be occurring with considerable delay. Increased awareness and education of caregivers, patients, and medical professionals are necessary to provide optimal management.
Copyright © 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28711194     DOI: 10.1016/j.anai.2017.06.001

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  10 in total

Review 1.  Emerging Therapies in Anaphylaxis: Alternatives to Intramuscular Administration of Epinephrine.

Authors:  Brittany Boswell; Susan A Rudders; Julie C Brown
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

Review 2.  Food-Induced Anaphylaxis: an Update.

Authors:  Christopher P Parrish; Heidi Kim
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-14       Impact factor: 4.806

Review 3.  Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities.

Authors:  Benjamin T Prince; Irene Mikhail; David R Stukus
Journal:  J Asthma Allergy       Date:  2018-06-20

4.  Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis.

Authors:  Marcus Shaker; Matthew Greenhawt
Journal:  JAMA Netw Open       Date:  2019-05-03

5.  APPEAL-1: A multiple-country European survey assessing the psychosocial impact of peanut allergy.

Authors:  Audrey DunnGalvin; Katharina Blumchen; Frans Timmermans; Lynne Regent; Sabine Schnadt; Marcia Podestà; Angel Sánchez; Pascale Couratier; Mary Feeney; Betina Hjorth; Ram Patel; Tessa Lush; Robert Ryan; Andrea Vereda; Montserrat Fernández-Rivas; Helen R Fisher
Journal:  Allergy       Date:  2020-07-09       Impact factor: 13.146

6.  A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020).

Authors:  Xiaotong Li; Qingbian Ma; Jia Yin; Ya'an Zheng; Rongchang Chen; Yuguo Chen; Tianzuo Li; Yuqin Wang; Kehu Yang; Hongjun Zhang; Yida Tang; Yaolong Chen; Hailong Dong; Qinglong Gu; Daihong Guo; Xuehui Hu; Lixin Xie; Baohua Li; Yuzhen Li; Tongyu Lin; Fang Liu; Zhiqiang Liu; Lanting Lyu; Quanxi Mei; Jie Shao; Huawen Xin; Fan Yang; Hui Yang; Wanhua Yang; Xu Yao; Chunshui Yu; Siyan Zhan; Guoqiang Zhang; Minggui Wang; Zhu Zhu; Baoguo Zhou; Jianqing Gu; Mo Xian; Yuan Lyu; Zhengqian Li; Hangci Zheng; Chang Cui; Shuhua Deng; Chao Huang; Lisha Li; Pengfei Liu; Peng Men; Chunli Shao; Sai Wang; Xiang Ma; Qiang Wang; Suodi Zhai
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.810

Review 7.  Clinical Management of Infant Anaphylaxis.

Authors:  Annette Carlisle; Jay Lieberman
Journal:  J Asthma Allergy       Date:  2021-07-08

8.  Association of Fatality Risk With Value-Based Drug Pricing of Epinephrine Autoinjectors for Children With Peanut Allergy: A Cost-effectiveness Analysis.

Authors:  Marcus Shaker; Matthew Greenhawt
Journal:  JAMA Netw Open       Date:  2018-11-02

9.  Determining Levers of Cost-effectiveness for Screening Infants at High Risk for Peanut Sensitization Before Early Peanut Introduction.

Authors:  Matthew Greenhawt; Marcus Shaker
Journal:  JAMA Netw Open       Date:  2019-12-02

10.  Physicians' knowledge regarding epinephrine underuse in anaphylaxis.

Authors:  Joaquin A Pimentel-Hayashi; Elsy M Navarrete-Rodriguez; Oscar I Moreno-Laflor; Blanca E Del Rio-Navarro
Journal:  Asia Pac Allergy       Date:  2020-10-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.